Aoxing Pharmaceutical Company Inc.
AXN
AXN was delisted on the 16th of October, 2017.
3 hedge funds and large institutions have $16K invested in Aoxing Pharmaceutical Company Inc. in 2013 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
50% more funds holding
Funds holding: 2 → 3 (+1)
6% less capital invested
Capital invested by funds: $17K → $16K (-$1K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
U
UBS
Zurich,
Switzerland
|
+$227 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$142 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $13K | -$142 | -538 | -1% |
|
|
EWM
2
Evercore Wealth Management
New York
| $3K | – | – | – |
|
|
U
3
UBS
Zurich,
Switzerland
| – | +$227 | +861 | New |
|
AXN Hedge Fund Activity: Q4 2013 in Review
3 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Aoxing Pharmaceutical Company Inc. (AXN) for Q4 2013, worth a combined $16K — down 5.9% from $17K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new AXN positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was UBS, opening a new position worth an estimated $227. The largest seller was Citadel Advisors, cutting an estimated $142.
- 3 institutional investors held Aoxing Pharmaceutical Company Inc. (AXN) as of Q4 2013, up from 2 in Q3 2013.
- Funds reported $16K of Aoxing Pharmaceutical Company Inc. stock for Q4 2013, down 5.9% quarter-over-quarter.
- 1 fund opened new Aoxing Pharmaceutical Company Inc. positions in Q4 2013 and 0 closed out, a net change of +1 holder.
- The largest Aoxing Pharmaceutical Company Inc. buyer in Q4 2013 was UBS, an estimated $227 added.
- The largest Aoxing Pharmaceutical Company Inc. seller in Q4 2013 was Citadel Advisors, an estimated $142 sold.
Based on aggregated 13F filings for Q4 2013.